145 related articles for article (PubMed ID: 25178944)
1. Change in ploidy status from hyperdiploid to near-tetraploid in multiple myeloma associated with bortezomib/lenalidomide resistance.
Pavlistova L; Zemanova Z; Sarova I; Lhotska H; Berkova A; Spicka I; Michalova K
Cancer Genet; 2014; 207(7-8):326-31. PubMed ID: 25178944
[TBL] [Abstract][Full Text] [Related]
2. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
Dimopoulos MA; Kastritis E; Christoulas D; Migkou M; Gavriatopoulou M; Gkotzamanidou M; Iakovaki M; Matsouka C; Mparmparoussi D; Roussou M; Efstathiou E; Terpos E
Leukemia; 2010 Oct; 24(10):1769-78. PubMed ID: 20739955
[TBL] [Abstract][Full Text] [Related]
3. Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient.
Yuan J; Shah R; Kulharya A; Ustun C
Leuk Res; 2010 Jul; 34(7):954-7. PubMed ID: 20138360
[TBL] [Abstract][Full Text] [Related]
4. Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance.
Mateos MV; Gutiérrez NC; Martín-Ramos ML; Paiva B; Montalbán MA; Oriol A; Martínez-López J; Teruel AI; Bengoechea E; Martín A; Díaz-Mediavilla J; de Arriba F; Palomera L; Hernández JM; Sureda A; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; Fernández M; García-Sanz R; Vidriales MB; Bladé J; Lahuerta JJ; San Miguel JF
Blood; 2011 Oct; 118(17):4547-53. PubMed ID: 21900193
[TBL] [Abstract][Full Text] [Related]
5. Sequence of novel agents in multiple myeloma: an instrumental variable analysis.
Baz R; Miladinovic B; Patel A; Ho VQ; Shain KH; Alsina M; Nishihori T; Ochoa-Bayona JL; Sullivan DM; Dalton WS; Djulbegovic B
Leuk Res; 2013 Sep; 37(9):1077-82. PubMed ID: 23809054
[TBL] [Abstract][Full Text] [Related]
6. Pomalidomide in the treatment of relapsed multiple myeloma.
Forsberg PA; Mark TM
Future Oncol; 2013 Jul; 9(7):939-48. PubMed ID: 23837756
[TBL] [Abstract][Full Text] [Related]
7. Novel agents for relapsed and/or refractory multiple myeloma.
Thomas SK; Richards TA; Weber DM
Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
[TBL] [Abstract][Full Text] [Related]
8. Treatment options for relapsed and refractory multiple myeloma.
Lonial S; Mitsiades CS; Richardson PG
Clin Cancer Res; 2011 Mar; 17(6):1264-77. PubMed ID: 21411442
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.
Berenson JR; Yellin O; Kazamel T; Hilger JD; Chen CS; Cartmell A; Woliver T; Flam M; Bravin E; Nassir Y; Vescio R; Swift RA
Leukemia; 2012 Jul; 26(7):1675-80. PubMed ID: 22354206
[TBL] [Abstract][Full Text] [Related]
10. Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen.
Shuqing L; Jianmin Y; Chongmei H; Hui C; Wang J
Exp Hematol; 2011 Dec; 39(12):1117-8. PubMed ID: 21920470
[No Abstract] [Full Text] [Related]
11. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
Sonneveld P; Hajek R; Nagler A; Spencer A; Bladé J; Robak T; Zhuang SH; Harousseau JL; Orlowski RZ;
Cancer; 2008 Apr; 112(7):1529-37. PubMed ID: 18300257
[TBL] [Abstract][Full Text] [Related]
12. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.
Richardson PG; Laubach JP; Schlossman RL; Ghobrial IM; Redman KC; McKenney M; Warren D; Noonan K; Lunde L; Doss D; Colson K; Hideshima T; Mitsiades C; Munshi NC; Anderson KC
Eur J Haematol; 2012 May; 88(5):446-9. PubMed ID: 22300348
[TBL] [Abstract][Full Text] [Related]
13. CXCR4 is a good survival prognostic indicator in multiple myeloma patients.
Bao L; Lai Y; Liu Y; Qin Y; Zhao X; Lu X; Jiang Q; Lu J; Huang X
Leuk Res; 2013 Sep; 37(9):1083-8. PubMed ID: 23849988
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients.
Kim K; Kim SJ; Voelter V; Suh C; Yoon SS; Lee JJ; Kwak JY; Ryoo HM; Kim YS; Moon JH; Park SK; Kim SH; Mun YC; Kim JS; Eom HS; Jo DY; Jun HJ; Kim KH; Lee JO; Lee JH; Min CK;
Ann Hematol; 2014 Jan; 93(1):113-21. PubMed ID: 24026427
[TBL] [Abstract][Full Text] [Related]
15. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Chen MH; Qi C; Reece D; Chang H
Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
[TBL] [Abstract][Full Text] [Related]
16. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
[TBL] [Abstract][Full Text] [Related]
17. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
18. The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network.
Tan D; Kim K; Kim JS; Eom HS; Teoh G; Ong KH; Goh YT; Durie BG; Chng WJ; Lee JH
Leuk Res; 2013 Sep; 37(9):1070-6. PubMed ID: 23816344
[TBL] [Abstract][Full Text] [Related]
19. The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.
An G; Li Z; Tai YT; Acharya C; Li Q; Qin X; Yi S; Xu Y; Feng X; Li C; Zhao J; Shi L; Zang M; Deng S; Sui W; Hao M; Zou D; Zhao Y; Qi J; Cheng T; Ru K; Wang J; Anderson KC; Qiu L
Clin Cancer Res; 2015 May; 21(9):2148-56. PubMed ID: 25652456
[TBL] [Abstract][Full Text] [Related]
20. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
